Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
(2014) In Urologic Oncology 32(8). p.1308-1316- Abstract
- Drug development and clinical decision making for patients with metastatic prostate cancer (PC) have been hindered by a lack of quantitative methods of assessing changes in bony disease burden that are associated with overall survival (OS). Bone scan index (BSI), a quantitative imaging biomarker of bone tumor burden, is prognostic in men with metastatic PC. We evaluated an automated method for BSI calculation for the association between BSI over time with clinical outcomes in a randomized double-blind trial of tasquinimod (TASQ) in men with metastatic castration-resistant PC (mCRPC).
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4691128
- author
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Urologic Oncology
- volume
- 32
- issue
- 8
- pages
- 1308 - 1316
- publisher
- Elsevier
- external identifiers
-
- pmid:25240761
- wos:000346627300031
- scopus:84925940426
- pmid:25240761
- ISSN
- 1873-2496
- DOI
- 10.1016/j.urolonc.2014.08.006
- language
- English
- LU publication?
- yes
- id
- bd341b2a-9021-40fc-afd0-7edcb89600c4 (old id 4691128)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25240761?dopt=Abstract
- date added to LUP
- 2016-04-01 09:57:53
- date last changed
- 2022-04-12 00:41:25
@article{bd341b2a-9021-40fc-afd0-7edcb89600c4, abstract = {{Drug development and clinical decision making for patients with metastatic prostate cancer (PC) have been hindered by a lack of quantitative methods of assessing changes in bony disease burden that are associated with overall survival (OS). Bone scan index (BSI), a quantitative imaging biomarker of bone tumor burden, is prognostic in men with metastatic PC. We evaluated an automated method for BSI calculation for the association between BSI over time with clinical outcomes in a randomized double-blind trial of tasquinimod (TASQ) in men with metastatic castration-resistant PC (mCRPC).}}, author = {{Armstrong, Andrew J and Kaboteh, Reza and Carducci, Michael A and Damber, Jan-Erik and Stadler, Walter M and Hansen, Mats and Edenbrandt, Lars and Forsberg, Göran and Nordle, Orjan and Pili, Roberto and Morris, Michael J}}, issn = {{1873-2496}}, language = {{eng}}, number = {{8}}, pages = {{1308--1316}}, publisher = {{Elsevier}}, series = {{Urologic Oncology}}, title = {{Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).}}, url = {{http://dx.doi.org/10.1016/j.urolonc.2014.08.006}}, doi = {{10.1016/j.urolonc.2014.08.006}}, volume = {{32}}, year = {{2014}}, }